Subscribe to AIM at Melanoma Foundation’s news feed.
Click on “Follow” and decide if you want to get news from AIM at Melanoma Foundation via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to AIM at Melanoma Foundation comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from AIM at Melanoma Foundation which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: AIM at Melanoma - Reshaping the Future Together - AIM at Melanoma Foundation
Is this your feed? Claim it!
RP1 (vusolimogene oderparepvec ) in combination with nivolumab to treat advanced melanoma is being considered for approval by the FDA for a third time. There is an Advisory Committee meeting scheduled for Thursday, July 30, 2026, for the FDA to hear from interested parties. These meetings give the committee information to help make their decision.
We understand that...
Every few months, Adam Harper sits down with a list of goals.
Some are ambitious. Others are simple: a trip he’d like to take, a book he wants to read, or someone he should call.
Then he starts making a plan.
The ritual is nothing new. Adam, a 31-year-old graphic designer who lives in Dallas, has always been a planner. He likes knowing where he’s headed n...
WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in co...
In May 2026 the American Academy of Dermatology (AAD) released results from the annual Practice Safe Sun Survey. The results show that many Americans continue to practice risky behaviors that are unfor...